According to the terms of the agreement, Ipsogen grants Arup non-exclusive rights, for the US territory, to offer a complete range of assays for the molecular classification and the screening of myeloproliferative neoplasms (MPN). Additional terms were not disclosed.
Vincent Fert, chairman and CEO of Ipsogen, said: “This agreement with Arup, reinforces the medical value of the JAK2 test as a diagnostic tool for MPN supported by the World Health Organization guidelines and affirms the strong intellectual property position of Ipsogen’s JAK2 patent portfolio.”